Method of correction of immune deficiency and prevention of gastrointestinal diseases of new-born calves
FIELD: veterinary medicine.
SUBSTANCE: method comprises giving to calves to drink the tincture of the combination herbal medicinal product - the grass of St. John's wort, meadowsweet, common yarrow, common nettle, rhizome of leather bergenia, root and rhizome of marsh cinquefoil, Scotch pine needles. At that the tincture fermented with microorganisms "EM Kurung" is used. The tincture is prepared by mixing 200 ml the tincture of the combination herbal medicinal product with 40 ml of the finished product "EM Kurung" and maintaining at the temperature of 18-20°C during the day, followed by filtration. EM-preparation "Baikal EM 1" is given to dry cows for 30 days prior to calving as a single dose in a dose of 30 ml/head. Mixoferon, sedimin and nitamin are additionally prescribed to new-born calves according to the following schedule: from the second feeding the tincture of the combination herbal medicinal product is watered with colostrum, fermented with microorganisms of EM-preparation "EM Kurung" at a dose of 150 ml/head dualfold for 10 days. On the 1, 2 and 8 day of life, mixoferon is injected intramuscularly at a dose of 9 ml/head. On the 1 and 8 day of life - nitamin and sedimin at a dose of 4 ml/head.
EFFECT: use of the claimed method enables to increase the immunobiological reactivity, energy of growth, provides prevention of gastrointestinal diseases of new-born calves.
4 tbl, 3 ex
The invention relates to veterinary medicine, relates to a method of correction of immune deficiency and prevention of gastrointestinal diseases calves and can be used for therapeutic and prophylactic protection of calves from mass illness and improve their safety.
Gastrointestinal pathology in young farm animals are disease of mixed etiology, caused by the increased virulence of opportunistic microorganisms and the influence of various associations of viruses, bacteria, chlamydia and Mycoplasma. The spread of these microorganisms, both in mixed form, and in various combinations, relatively high, caused by disease of mass character. The occurrence of illness, degree of coverage of the population, the severity and outcome depend on the body condition of the animal, the level of natural resistance and those conditions in which the calf gets after birth and in the subsequent periods of cultivation. High level of resistance of newborn calves is provided by a combination of many factors, among which is of paramount importance to the physiological condition of the mother's body. Prevention of diseases of young animals is complicated by the fact that the body of the newborn effect of morpho-functional features in early postnatal PE is the iodine is poorly adapted to adverse environmental conditions.
Known medicinal solutions, preparations and mixtures used for the prevention and treatment of gastrointestinal diseases of young farm animals containing antimicrobial drugs, minerals, vitamins, protein preparations, etc. used in different versions /1/. However, the application of these therapeutic and preventive interventions are carried out mainly on a separate etiologic or pathogenic aspects of the disease, which reduces the effectiveness of prevention. To reduce the impact of infectious agents, recovery of intestinal normalize and metabolic disruptions in veterinary practice is widely used probiotics, for example, Lactobacterin (lyophilized microbial mass of live antagonistically active Lactobacillus Lb.fermenti and Lb.plantarum) /2/, bifidobakterii (dried weight antagonistically active bacteria B. bifidum No.1, No. 791, two-3) /3/, lactometer (mixture of live acidophilus and bifidobacteria, dried by means of sorption on natural plant media), biharilal (lyophilized Lactobacillus bulgaris, Lactobacillus acidophilus, Lactobacillus fermentum, Bifidobacterium bifidum) /4/. The main disadvantage of probiotics is that their use for the prevention of gastrointestinal diseases is not always accompanied by a positive effect because of the constraints is nasty spectrum antagonistic activity and immunodeficiency States calves. Expanding the range of pharmacological effects is provided by EM-drugs, for example, the drug "Baikal EM-1, which is a sustainable community of effective microorganisms, including symbiotic complex of 86 strains of microorganisms /5/, drug ' EM Kurung" /6/representing natural milk product containing the symbiosis of bifido-, lacto-, acetic-, propionic acid and other bacteria, lottostrategies, yeast, enzymes, amino acids and vitamins. Known probiotic preparations with active phytocomplexes, such as feed additive "Velena, including probiotic preparation of Lactometer and dietary Spirulina VAL" /7/, the drug for young farm animals, including probiotic preparation bifidobakterii and krioporoshok oats /8/. Infusion drug collection (St. John's wort, yarrow, nettle, kidney pine, Comarum palustre, meadowsweet, bergenia), fermented drug ' EM Kurung", include the complex of therapeutic and preventive interventions for gastro-intestinal diseases of calves /9/. Active phytocomplex included in the composition to known drugs are components necessary for normal intestinal microflora (food substrates and regulators of metabolism own intestinal microflora), but they do not have virginiamoreno properties and sufficient impact on the mechanisms of the antioxidant defense system.
The etiology and characteristics of the pathological process (reduction of local and General immune status of animals, activation of free radical mechanisms and lipid peroxidation, development intoxication processes) mass diseases of young farm animals require an integrated approach to their treatment and prevention, allowing to take into account the structure of pathogens (included in the range of vaccines, serums) and the factors contributing to the emergence and development of diseases (included in the set of drugs that stimulate and corrective immunity, normalizerbase metabolism, the functioning of organs and systems, and so on).
Task, which is aimed at solving the invention include a method for correcting immune deficiency and prevention of gastrointestinal diseases of calves with the use of biocompatible, safe and environmentally friendly products.
The technical result consists in increasing the efficiency of prevention of gastrointestinal diseases calves normalization immunobiochemical homeostasis in cows in the second half of pregnancy and increase natural resistance and immune status of newborn calves.
The method is as follows.
Dry cows within 30 days before calving on the continuously applied EM-drug "Baikal EM-1 in a dose of 30 ml/goal., and newborn calves in the second feeding colostrum feeding infusion drug collection (the herb of St. John's wort, meadowsweet, yarrow, nettle, rhizomes of bergenia tolstolistnogo, roots and rhizomes of marsh cinquefoil, needles of Scots pine) (photonasty), fermented by microorganisms of the drug "EM-Kurung", at a dose of 150 ml/goal. twice within 10 days, 1, 2, and 8 life intramuscularly injected mixoterin dose of 9 ml/goal., 1 and 8 day life - vitamin, cedimin at a dose of 4 ml/bird.
"Baikal EM-1" - probiotic preparation, representing an evolutionary existing self-regulating and self-replicating complex of 86 strains of microorganisms. To prepare working solution of 40 ml of concentrate "Baikal EM-1" mixed with 4 liters of warm (26-30°C) non-chlorinated water, the solution add a nutrient medium (molasses) at the rate of 2 tablespoons per liter and thoroughly mixed, followed by incubation for 4-6 days at a temperature of 26-30°C.
Photonasty, fermented by microorganisms "GM-Kurumi", prepared by mixing 200 ml of infusion drug collection (the herb of St. John's wort, meadowsweet, yarrow, nettle, rhizomes of bergenia tolstolistnogo, roots and rhizomes of marsh cinquefoil, needles with the dreams of the ordinary) with 40 ml of the finished product "EM-Kurung" and aged at a temperature of 18-20°C during the day with subsequent filtering.
Immunostimulant "Mixoterin" is a mixture of proteins leukocyte interferon obtained by microbiological synthesis, which is used for prophylactic and therapeutic purposes in the gastro-intestinal and respiratory diseases of different etiology in cattle, sheep, pigs and their young /10/.
Sedimen is an aqueous mixture of compounds of iodine and selenium in stabilizing the basis geisterstreiber complex, which is used for the prevention and treatment of iron deficiency anemia, white-muscle disease, goiter, dystrophy of the liver in all species of farm animals /11/.
Vitamin contains: active substances: vitamins A, D3, E, C, and auxiliary components and is used to compensate for the deficiency of vitamins in the organism of animals /12/.
The effectiveness of the method was determined in the research-and-production experiments in conditions of households, long prone to gastro-intestinal diseases of newborn calves (incidence - 90-100%; mortality - 30-55%), and were evaluated on key clinical indicators and indicators immunobiochemical homeostasis: total protein (determined refractometric method, glucose - orthotoluidine method), total lipid was determined by Krinitsky A. F. modification Volgina Century. And.), cholesterol (defined by ILC), BAC is echidna activity of blood serum (determined by Smirnova O. C. and Kuzmina T. A.), the authors estimated the effect activity of blood serum (determined by Dorofeyuk Century BC), the phagocytic activity of leukocytes (determined by Plamenco S. I., Sidorov Century A.D.), T - and b-lymphocytes (defined by Mayansky A. N., Russanova S. P.), hemoglobin (defined hemiglobincyanide method), total calcium (defined standardized colorimetric method), inorganic phosphorus (determined molybdenum UV method), erythrocytes (determined by turbidimetric method), leukocytes (determined by counting in the Goryayev camera). As the primary marker assessment of endogenous intoxication applied Index Endotoxicosis - the ratio of the level of molecules of average weight (MSM) in the serum when the optical density at 254 nm and 280 nm (Gabrielian N. And.). The received digital data were processed by the method of variation statistics.
The essence of the method is illustrated by examples.
Example 1. In terms of economy formed two groups of cows on 50 goals each in the last month of pregnancy - experimental and control. Cows of the experimental group in addition to the normal diet has given the drug "Baikal EM-1 in a dose of 30 ml within 30 days prior to calving, the cows of the control group was kept on a normal diet, additional drugs were received. Calves from cows in both groups were divided into two groups - experimental and control. Calves experience the Oh group, starting from the second feeding colostrum was drinking photonasty, fermented by microorganisms of the drug "EM-Kurung", at a dose of 150 ml/goal. twice within 10 days, 1, 2, and 8 life was intramuscularly injected with mixoterin dose of 9 ml/goal., 1 and 8 days of life - vitamin, cedimin at a dose of 4 ml/goal. The calves of the control group of drugs not prescribed.
Calves (first group: 40 Gol.), obtained from cows of the control group, were born with obstetrics, weighing 35-40 kg, which corresponded to the norm. However, the majority of calves (30 goals) were sluggish, inactive, did not seek to receive colostrum, sucking reflex was poorly expressed, muscles flabby, loose. 8 calves observed indigestion, and 2-3 days of diarrhea were recorded in all calves. 6 calves fell from dehydration at the age of 5-10 days. Liveweight gain was for the first month experience 350 grams per day. Calves (second group: 49 Gol.), born from cows of the experimental group, were born themselves, almost immediately stood up, they manifested a distinct sucking reflex. Muscles were firm, they had a good appetite. Diarrhoea had in the first days of life 5 calves, one calf fell from dehydration. Liveweight gain was for the first month experience 495 grams per day.
Example 2. In terms of economy, troubled by disease of young cattle, formed the 4 groups of calves at 20 goals each, born from cows treated with GM-drug "Baikal EM-1 as in example 1, and not treated with drugs. The first group of calves born from cows not treated with GM-drug "Baikal EM-1", which from the second feeding with colostrum was drinking photonasty, fermented by microorganisms of the drug "EM-Kurung", at a dose of 150 ml/goal. twice within 10 days, 1, 2, and 8 life intramuscularly injected mixoterin dose of 9 ml/goal., 1 and 8 day life - vitamin, cedimin at a dose of 4 ml/goal. The second group of calves born from cows treated with GM-drug "Baikal EM-1 as in example 1, which drugs were prescribed. The third group: calves born from cows treated with GM-drug "Baikal EM-1 as in example 1, which from the second feeding with colostrum was drinking photonasty, fermented by microorganisms of the drug "EM-Kurung", at a dose of 150 ml/goal. twice within 10 days, 1, 2, and 8 life was intramuscularly injected with mixoterin dose of 9 ml/goal., 1 and 8 day life - vitamin, cedimin at a dose of 4 ml/goal. The fourth group: calves born from cows not treated with GM-drug "Baikal EM-1", which drugs were prescribed. For the calves were clinical observations, given the number of diseased calves and average daily gain in live weight. The results are presented in table 1.
|Dynamics of diseases and growth of calves|
|Indicators||Groups of calves|
|1st group:||2nd group||group 3||4|
|The number of calves that goal.||20||20||20||20|
|with the attendance||17||2||2||18|
|Daily gains, g||475,0±11,7||395,0±30,5||570,0±15,4||351,0±19,5|
6 calves from each group took the blood on immunobiological studies at the age of 5 and 15 days. The received digital data processed by the method of variation statistics. The results are presented in table 2.
|Groups of calves|
|Indicators||1st group||2nd group||group 3||4|
|age 5 days|
|The content of total protein, g/l||51,2||56,6||60,3||46,50|
|Hemoglobin, g/l||101,0||to 106.0||112,0||90,00|
|FOREPLAY, %||4,01||of 5.05||7,22||3,38|
|age 15 days|
|The content of total protein, g/l||60,30||56,30||73,20||43,80|
|FOREPLAY, %||4,75||and 5.30||6,82||2,80|
As can be seen from table 2, in calves born from cows not treated with GM-drug "Baikal EM-1 (groups 1 and 4), all initial indicators were below the physiological norm. the lower indicators total protein content testified about violations of protein metabolism, and reduced levels of hemoglobin were signs of anemia. In calves the first group treated with the drugs in accordance with the invention, all biochemical parameters of blood gradually diminished to the level of the upper limits of physiological norm. Optimum performance was observed in calves 3 groups born from cows treated with GM-drug "Baikal EM-1", who were prescribed medication in accordance with the invention. Analysis of the main indicators of non-specific immunity (BASK and CARESSES) showed that they varied depending on age. The highest level of non-specific immunity in all age periods was in the third group. So, 15 days of age indicators BASK and CARESSES was 96,3 and 6,82%, respectively, compared to control - 73,9% and 2.8%, respectively (group 4). In the 2nd group respectively 81,2 and 5.3%, and 1-Oh group, respectively 89,2 and of 4.75%. Indicators of nonspecific immunity in calves of the first group, who were prescribed medication in accordance with the invention, was at the level of physiological norm, indicating that the positive effect of the combined use of Finasta, fermented by microorganisms of the drug "EM-Kurung", mixoterin, vitamina and sedimen stated in the scheme on the development of natural resistance.
Example 3. Of calves, radius is, for example by transferring them from the cows, receiving GM-drug "Baikal EM-1", formed 4 groups. Calves were prescribed these drugs for different schemes: 1 group: calves in the second feeding with colostrum was drinking photonasty, fermented by microorganisms of the drug "EM-Kurung", at a dose of 150 ml/goal. twice within 10 days, 1, 2, and 8 life was intramuscularly injected with mixoterin dose of 9 ml/goal., 1 and 8 days of life - vitamin, cedimin at a dose of 4 ml/goal; group 2: calves, since the second feeding colostrum, colostrum was drinking the drug "Baikal EM-1 in a dose of 20 ml/goal. twice within 10 days, 1, 2, and 8 life was intramuscularly injected with mixoterin dose of 9 ml/goal., 1 and 8 day life - vitamin, cedimin at a dose of 4 ml/goal; group 3: calves 1, 2 and 8 life was intramuscularly injected with mixoterin dose of 9 ml/goal. 1 and 8 day life was intramuscularly injected with nitamin, cedimin at a dose of 4 ml/bird.; group 4: calves drugs were not administered (control). For the calves were clinical observations. Status of newborn calves was assessed by weight gain, clinical, and biologic indicators. The results are presented in tables 3 and 4.
|Dynamics of diseases and growth of the calves, depending on the range of medicines|
|Groups of calves|
|Indicators||1-I: photonasty, fermented by microorganisms of the drug "EM-Kurung", mixoterin, vitamin, cedimin||2-I: the drug "Baikal EM", mixoterin, vitamin, cedimin||3-I: mixoterin, vitamin, cedimin||4-I: without drugs|
|The number of animals that goal.||15||15||15||15|
|Ill dyspepsia, goal (%)||3 (20,0)||6 (40,0)||12 (80,0)||14 (93,3)|
|The duration of illness, days.||3||4||5||7|
|Palo goal. (%)||1||2||3||6|
|Average daily weight gain, g||580±2,3||560±5,4||510±6,8||425±2,2|
|Immunobiochemical the blood of calves in the early postnatal period in a variety of ways to prevent gastrointestinal diseases|
|Indicators||The physiological norm||Groups of calves|
|1: fit the flask, fermented microorganisme drug "EM-Kurung", mixoterin, vitamin, cedimin||2-I: the drug "Baikal EM-1", mixoterin, vitamin, cedimin||3-I: mixoterin, vitamin, cedimin||4-I: without drugs|
|Total protein serum, g/l||55-70|
|Total lipids, g/l||3.5 to 4.5|
|Total cholesterol, mmol/l||2,6-3,6||
|The total calcium, mmol/l||2,7-3,2|
|The inorganic phosphorus, mmol/l||1,5-2,0|
|The authors estimated the effect activity of blood serum, %||2-5|
|Bactericidal activity of blood serum, %||89-100|
|Phagocytic activity, %||60-80|
|General the e immunoglobulins, mg/ml||25-30|
|Note 1. In the numerator presents data obtained prior experience at the age of 1-2 days, the denominator of 10-12 days after the experience.|
|Note 2. Shows the statistical significance of the difference in the performance of the experimental groups and the control group: *<0,001, **<0,05, ***>0,05.|
As can be seen from table 3, the number of newborn calves, participated in the experiment, dyspepsia ill 58,3%. In the control group the incidence of calves with dyspepsia amounted to 93.3%, in the 2nd experimental - 40%, in the 3rd experimental 80% while in the 1st experimental group - 20%. It was found that in the control group at the age of 2 days ill 8 calves, to the 3 rd day of life is still 6 calves. On the 5th and 6th days of life calves, the number of patients decreased to 4 and 3 calves. On the 7th day of life were ill 1 calf. Disease of newborn calves in the control group lasted from 5 to 7 days. Repeated symptoms of dyspepsia occurred in 50% of calves in 2-3 days. after the first parabolani. The incidence of calves with dyspepsia in the 1st experimental group was 20%. Calves are sick dyspepsia on the 3rd day of life. The duration of dyspepsia in this group was 2 to 3 days. Dyspepsia was spent mostly in the form of light. In calves in this group is not marked re-development of symptoms of dyspepsia. In the second experimental group of calves on day 2 of life ill 3 calf, to the 3 rd day of life - 2 more calves for 4-th day of life 1 calf. 4 calves disease was spent in light, 2 calves in a severe form. On the 3rd day from the date the illnesses, the disappearance of signs of dyspepsia observed in 1 calf. 3 calves recovery occurred on the 4th day after the start of treatment. In the 3rd experimental group on day 2 of life ill 8 calves, to the 3 rd day of life - 4 calf. 7 calves were recorded track, 5 - severe form of parabolani. Recovery 4 calves were observed on 4, 5 on the 5th day. In patients with dyspepsia calves of the control group General condition was poor, the appetite of most calves were absent, there were signs of exhaustion by the end of the disease, the animals were lethargic, skin elasticity is reduced, the skin and mucous membranes pale. All diseased calves were observed diarrhoeal syndrome. The stool was runny, stinky. Only 7-th and 9-th day since the disease was advancing improvement: diarrhoeal syndrome was weakly expressed, appetite. However, when re-development of clinical signs of diarrhea in calves appeared severe diarrhea, with fetid odor, no appetite. The General condition of the oppressed. In the 1st experimental group got sick newborn calves General condition was good. Animals were active, the inhibition was absent. Calves were observed good appetite. Faeces were liquid, but on the 2nd and 3rd days of the disease they are more decorated, bought the natural color and smell. Visible mucous membranes were pink, skin elasticity saved. Newborn calves 2nd experience the Oh groups of the General condition of the calves was satisfactory. A good appetite, fecal masses on the first day of illness were liquid, odor, specific sharp. In subsequent days, defecation gradually came back to normal, fecal became more decorated. The improvement of the General condition was noted to the 3 rd and 5-th day since the onset of the disease. In diseased calves 3rd group noted decreased appetite, lethargy, weakness, long a lie, shortness of cardiac activity, profuse diarrhea with frothy liquid stool with admixture of mucus at first yellow, then green color with fetid odor, sometimes mixed with blood. Cal stands out spontaneously. 4-5 days after the start of treatment, appetite, and faeces acquired formed. Relapses in the 3rd group was 25%. Studies have confirmed the effectiveness of the inventive method: the exception or substitution regimen of one or more drugs was reduced clinical parameters.
Table 4 shows that the level of hemoglobin after the experience of the first calves of the experimental group increased in comparison with the original data by 19% and was significantly higher by 15% compared with the control and 14% compared to the third experimental group. In calves the second experimental group, the hemoglobin level increased by 8% and was higher by 6.7% compared with the control. Growth dynamics of hemoglobin in calves third experienced and the completed groups was less pronounced and was 2.2% and 1.9% respectively. Indicators of erythrocytes by the end of the experiment in the experimental group increased to physiological minimum, in the first experimental group - by 11.3%, in the second - 9.9%, and the third at 1.3% and increased in comparison with control by 9.4%, to 2.8% and 1.9%. The total protein content in the blood serum of calves first and second experimental groups was 10.7% and 7.6% and reached norms. The glucose content in the blood of the calves of the first and second experimental groups to the end of the experiment increased by 17.5% and 34%, being significantly higher at 42% and 83% compared with the third experimental group and 22% and 56.2 per cent in comparison with the control and reached the level of the physiological norm. In calves third experimental and control groups increase glucose level was less pronounced and was 3% and 10.2%, respectively, and at the end of the experiment was below the physiological norm. The lipids to the end of the experiment increased in all experimental groups, the first of 55%, the second at 62% and the third at 152%. The highest values were obtained in the third experimental group of calves that were significantly higher by 15% compared with the control group. A similar trend was observed in the level of cholesterol in laboratory animals. By the end of the experience in all experimental groups, he approached the physiological minimum, up 72%, 19% and 53% respectively, while in control group there was a decrease cholesterol by 27%. The best is the simple obtained in the first experimental group of animals, where the amount of cholesterol was significantly exceeded the similar indicator of the calves of the control group by 63%. Thus, the dynamics of the indicators in the first experimental group (the claimed method) testified to the normalization of carbohydrate and lipid metabolism at the upper limit of the physiological norm. In the study of mineral metabolism in calves in all groups showed lower levels of total calcium and inorganic phosphorus, and the violation of the calcium-phosphorus relationship due to an excess of phosphorus, which is caused by unbalanced diets of cows mothers. The indices of nonspecific resistance of all experimental groups increased significantly compared with the control. The authors estimated the effect activity of blood serum in the experimental calves increased 3.3 (the first group), 4.4 (second group), 3 (third group) times and was significantly higher than the control at 57%, 81% and 36%, respectively. Bactericidal activity of blood serum in calves of all groups was within the physiological norm, but in the third experimental and control groups, it was not significantly significant increase during the experience, and the calves of the first and second experimental groups 20 days after the start of the experiment increased by 4.7% and 8.7% compared with the control was significantly higher at 5.1% and of 10.25%, respectively. Phagocytic activity of leukocytes from calves of the control group was below the physical and the ideological norms, whereas in the experimental groups, it increased towards the end of the experience, and 75.5%, 60.7 per cent and 52.7%, respectively. The greatest increase in phagocytic activity was observed in the first experimental group. It increased compared to control at 52%. Indicators of the content of total immunoglobulins in calves first and second experimental groups significantly exceeded the similar indicator of the calves of the control group 93 and 105%, respectively, due to a significant increase to the 20-th day experience of 149.5% and 148%, respectively. The number of T-lymphocytes in calves first and second experimental groups during the experience has increased 2.7 times, significantly exceeding the corresponding figures of calves from control and three experimental groups 24.8 and 40.8%, respectively. The most pronounced changes in the level of b-lymphocytes was also in calves first and second experimental groups at 109% and 56%, respectively. Index endotoxicosis (the ratio of the level of molecules of average weight (MSM) in the serum when the optical density at 254 nm and 280 nm) in the first and second experimental groups by the end of the experience remained within the normal range, whereas in the control and three experimental groups increased by 19.5% and 13.2%, respectively, indicating that the development of inflammatory processes in the body calves.
Experimental data confirmed the high prophylactic efficacy of the claimed method, which benefits the giving selection of drugs, their sequences and modes of application allows to take into account the following features of an organism of the newborn calf: failure factors, antioxidant (vitamin E, ceruloplasmin, glutathioneperoxidase), contributing to excessive accumulation of products of lipid peroxidation and contributing to the violation of phagocytosis due to structural rearrangement of the cell membranes of phagocytes; physiological immunodeficiency due to the lack of blood immunoglobulins to obtain a sufficient number of full maternal colostrum; the sterility of the intestine, the settlement of which the resident microflora (bifidobacteria and lactobacilli) occurs gradually and ends 20-25 days after birth, and in the first days of life intestine is inhabited mainly by enterobacteria, enterococci, other aerobic microorganisms ("khlevnoy" microflora) that subsequently leads to dysbiosis, clinically manifested by diarrhea, bacterial toxicosis and often followed by septicemia. The inclusion in the scheme of prevention of Finasta, fermented by microorganisms EM-drug "EM-Kurung", not only ensures the dominance of species of microorganisms that inhabit the gastrointestinal tract, thereby regulating physiological balance of intestinal flora, but p is degenerescence action (binder, antispasmodic, analgesic, calming the nervous system, normalizing the activity of the gastrointestinal tract, relieving inflammation in the intestines and promote the regeneration of epithelium). Immunomodulator with antiviral activity mixoterin, b complex vitamins (vitamin) and the complex of microelements (cedimin) contribute to the prevention of stress reaction on the background violated immunobiochemical homeostasis.
Sources of information taken into account
1. C. M. Subbotin, S., Subbotina, I. D. Alexandrov. Modern medicines in veterinary medicine. - Rostov-on-don: Phoenix, 2001. - 600 C.
2. Guidance on the application of Lactobacterin dry in veterinary medicine, appr. The BS Gosagroprom USSR 19.05.1989.
3. Interim guidance on the application of bifidobacteria dry in veterinary medicine, appr. The BS Gosagroprom USSR 19.05.1989.
4. Application No. 97101157 A, 1999.
5. Interim guidance on the use of probiotic Baikal EM-1 in veterinary medicine, appr. 22.12.2005,
7. Materials of scientific-practical conference 14-16.09.2004 New in the epizootiology, diagnosis and prevention of infectious and non-infectious diseases of poultry in commercial poultry production", S.-Petersburg-Lomonosov. 2004, S. 192-193.
8. RU # 2231362 C2, 2004.
9. RU # 2377005 C1, 2009.
10. Instructions for use of mixoterin - www.vetlek.ru
11. The instruction on application is sedimen - http://www.vetlek.ru
12. Instructions for use of nitamin - http://www.vetlek.ru
Treatment of immune deficiency and prevention of gastrointestinal diseases of newborn calves, including feeding their drug infusion collection - herb St. John's wort, meadowsweet, yarrow, nettle, rhizomes of bergenia tolstolistnogo, root and rhizomes of marsh cinquefoil, needles of Scots pine, characterized in that use brew, fermented by microorganisms "GM-Kurumi", which is prepared by mixing 200 ml of infusion drug collection with 40 ml of the finished product "EM-Kurung" and aged at a temperature of 18-20°C during the day followed by filtration, when this dry cows within 30 days prior to calving once applied EM-drug "Baikal EM-1 in a dose of 30 ml/goal., and newborn calves additionally given mixoterin, cedimin, nitamin according to the following scheme: from the second feeding with colostrum feeding infusion drug collection, fermented by microorganisms EM-drug "EM-Kurung", at a dose of 150 ml/goal. twice within 10 days, 1, 2 and 8 days of life intramuscularly injected mixoterin dose of 9 ml/goal., 1 and 8 day life - vitamin, cedimin at a dose of 4 ml/goal.
SUBSTANCE: pathogenetic treatment of chronic tonsillitis and/or hypertrophy of palatine tonsils in preschool children suffering from lymphoproliferative syndrome is ensured by the palatine tonsils debridement. An interleukin-1β(IL-1β) level is measured in the palatine tonsils washing. If the measured value is less than 5.8 pg/ml, recombinant interleukin-1β (IL-1β) is to be administered orally by phonophoresis with the use of the Tonsillor MM apparatus. Two courses of 10 procedures every 14 days are performed. The clinical effectiveness is assessed if observing a positive dynamics of IL-1β measured in the palatine tonsils washing 17 and 41 days after the beginning of the immunomodulatory therapy.
EFFECT: higher clinical effectiveness ensured by the differentiated selection of children for carrying out the immunomodulatory therapy, reducing a rate of infectious involvements of the palatine tonsils in the declared group of patients by the pathogenetically reasoned application of recombinant IL-1β.
3 cl, 2 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to biotechnology and represents a pharmaceutical composition applicable for treating a rheumatic disease and containing the humanised anti-CD4 antibody able to activate CD4+CD25+ regulatory T-cells, and methotrexat. The present invention also discloses a kit and a method of treating the rheumatic disease with using the above pharmaceutical combination and the above kit.
EFFECT: invention enables implementing more effective methods of treating the rheumatic diseases, including rheumatoid arthritis.
57 cl, 8 dwg, 2 tbl, 2 ex
SUBSTANCE: invention refers to medicine, namely to oncology, and concerns treating the patients suffering oncological diseases by administering the preparations inducing active cellular immune stimulation. The preparations are administered in the form of lyophilised lysate of gram-positive enteric bacteria enclosed in gelatine capsules. That is combined with correcting intestinal dysbacteriosis, administering antioxidants, vitamins and minerals, as well as nutrient-enriched protein food, amino acid L-arginine, and pectin- and fibre-enriched vegetable food.
EFFECT: method provides higher clinical effectiveness of the patients suffering the oncological diseases with no side effects.
SUBSTANCE: developed agent contains trophoblastic β-1-glycoprotein (TBG), immunoglobulin (Ig) and additionally contains tetrapeptide H-Tyr-X-Y-Glu-OH, wherein X - Gln and/or Glu, Y - Cys (acm) and/or Cys.
EFFECT: effective treatment of autoimmune diseases by single doses containing TBG 1 mg, Ig 19 mg and tetrapeptide 20 mg.
6 tbl, 13 ex
SUBSTANCE: group of inventions refers to veterinary science and aims at normalising metabolic processes, stimulating immune system and blocking mechanisms of infectious process with a risk of endogenous infection activation. A method for producing a combination immunometabolic preparation with anti-infectious activity involves dissolving succinic acid and levamisole in demineralised water with formalin added. According to the other aspect of the invention, the immunometabolic preparation additionally contains polyethylene glycol. The ingredients are used in the declared ratio.
EFFECT: using this group of inventions provides producing an injection form of the immunometabolic preparation with anti-infectious activity.
2 cl, 3 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the chemical-pharmaceutical industry and represents a method of obtaining a complex preparation for the application in veterinary, possessing immunomodulating and antiseptic properties, which includes mixing succinic acid, levamisole and formalin in distilled water with the following component ratio, wt %: levamisole - 3.0%-3.5%; succinic acid - 2.0%-2.5%; formalin - 0.3%-0.5%, distilled water - the remaining part; sterilisation of the solution by autoclaving is performed in a mode of 1 atm for 20 minutes.
EFFECT: elaboration of the method of obtaining the complex preparation for the application in veterinary, possessing immunomodulating and antiseptic properties.
FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed group of inventions relates to medicine, namely to therapy and immunology, and deals with treatment of autoimmune diseases. For this purpose 3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid or its salt is introduced in the form of a combination or a pharmaceutical composition with one or more of TNFα inhibitors.
EFFECT: invention provides efficient treatment of autoimmune diseases due to synergic action of the said components.
6 cl, 1 ex, 1 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the pharmaceutical industry, namely to a personal preparation from earthworms for treatment of diabetes. The method of obtaining the personal preparation from earthworms for treatment of diabetes includes placement of sexually mature earthworms in a medium, consisting of organics, which additionally contains a solution of a patient's urine, after that, the sexually mature earthworms are removed and for 3 months each 7-10 days fresh organic food is added to the remaining mass, after that, the sexually mature earthworms are separated, placed in a reservoir and sprayed with an alcohol solution, mixed, poured with the alcohol solution and placed into dark place under the specified temperature, with the solution being mixed daily, with further separation of the extract from the sediment. The personal preparation for treatment of diabetes.
EFFECT: application of the described above preparation increases efficiency of diabetes treatment.
3 cl, 3 dwg, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, more specifically to a pharmaceutical composition possessing antithrombotic, thrombolytic, immunomodulatory, anti-inflammatory action, normalising lipid and carbohydrate metabolism, more specifically to the pharmaceutical composition of the substance Pijavitum (hereinafter referred to Pijavitum) made from lyophilised medicinal leech. The above pharmaceutical composition is presented in the form of an enteric coated tablet.
EFFECT: coating prevents the active ingredients of Pijavitum from destruction under action of the enzymes and acid medium of the stomach.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a new antineoplastic drug representing 2-isobutyl-4,6-dimethyl-5-oxypyrimidine of the general formula I specified below. The drug may be used for an adjuvant antineoplastic immune therapy. The invention also refers to a method for preparing 2-isobutyl-4,6-dimethyl-5-oxypyrimidine. According to the method, isocaproic acid amide reacts in ice-cold acetic acid with chloracetyl acetone to form the respective oxazole which reacts with aqueous ammonia which leads to preparation of the above compound.
EFFECT: what is disclosed is a manifested tumour growth inhibition with no signs of the toxic effect on somatic characteristics of tumour-carrier mice.
3 cl, 9 tbl, 6 ex
FIELD: packaging industry.
SUBSTANCE: present invention relates to packaging products sensitive to moisture. The probiotic product comprises lyophilised lactic acid bacteria mixed with anhydrous powder for solution for oral rehydration. At that the lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration are packaged in foil with a desiccant integrated into the foil. Also the method of long-term storage of viable lyophilised probiotic lactic acid bacteria is provided. The method comprises providing the anhydrous powder for solution for oral rehydration; mixing lyophilised lactic acid bacteria with anhydrous powder for solution for oral rehydration; packing the mixed lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration in the package comprising the chemical desiccant material inserted into a layer of foil; and sealing the package.
EFFECT: invention enables to extend the shelf life of the probiotic product.
13 cl, 1 dwg, 1 tbl, 4 ex
SUBSTANCE: invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, having physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterise butyrate.
EFFECT: novel compounds have an easily weighable form, are stable to acids and alkalis and are capable of releasing the acid in the small and large intestines continuously over a long time.
7 cl, 5 dwg, 15 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: pharmaceutical composition for the reduction of a primary radiation response and an early transient incapacity containing ondansetron and gastrozepin in mass ratio 1-12:2-15; the composition is used as an injectable dosage form.
EFFECT: what is developed is the new composition.
3 cl, 3 tbl, 2 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, particularly to using probiotics in the manufacture of a drug or a therapeutic nutritional composition for long-term prevention of diarrhea in infants. Using the probiotic Lactobacillus rhamnosus ATCC 53103 or Lactobacillus rhamnosus CGMCC 1.3724, and the probiotic Bifidobacterium longum ATCC BAA-999 in the manufacture of a drug or a therapeutic nutritional composition to be introduced into an infant for at least three months for the purpose of long-term prevention of diarrhoea, wherein the probiotic is introduced into a breastfeeding infant from a nursing mother.
EFFECT: using the above probiotic strains from the nursing mother is effective for the purpose of long-term prevention of diarrhoea in infants.
6 cl, 2 ex
SUBSTANCE: invention refers to veterinary science, and aims at treating viral diseases in animals. What is declared is a composition for treating viral diseases in animals, containing two subtypes of vertebrate recombinant interferon mixed in equal molar proportions.
EFFECT: use of the declared composition enables ensuring the substantial increase of the therapeutic effect of recombinant interferons and minimising the potential adverse effects associated with their use.
SUBSTANCE: what is presented is the use of the strain Lactobacillus johnsonii in preparing a probiotic composition for prevention of postoperative abdominal and pelvic infections caused by pelvic liquid accumulation, anastomosis leakage, or caused by bacterial translocation.
EFFECT: colonic L Johnsonii Lai colonisation in the patients underwent colectomy for colorectal adenocarcinoma.
11 cl, 1 dwg, 1 tbl, 2 ex
SUBSTANCE: invention relates to feeding of newborn babies delivered by Caesarian section. Claimed is change of composition which contains long-chain polyunsaturated fatty acid and, at least, one substance, selected from group, consisting of (a) nucleotide and (b) nucleotide precursor, selected from group consisting of nucleotides, purine bases, pyridine bases, ribose and deoxyribose for obtaining composition for introduction to newborn baby delivered by Caesarian section, for treatment and/or prevention of infection, diarrhea, intestine phlegmon, allergy, atopic eczema, asthma, allergic rhinitis and/or allergic conjunctivitis. Composition can also be used to improve intestinal maturation, reduction of intestinal permeability and/or for treatment of disorders associated with intestinal barrier, in newborn baby delivered by Caesarian section. Introduced to newborn baby composition is not human breast milk.
EFFECT: invention makes it possible to improve intestinal flora of newborn babies, delivered by Caesarian section.
12 cl, 5 tbl, 6 ex
FIELD: food industry.
SUBSTANCE: invention relates to food industry and deals with alimentation of children born by cesarean section. One proposes application of a composition including indigestible oligosaccharides to produce a composition for treatment and/or prevention of diseases with children born by cesarean section. The disease is selected from the group including asthma, allergy, infection and atopic dermatitis. Indigestible oligosaccharides content in the composition is 0.5 - 75 g per 100 g of dry weight of the composition. Alternatively the composition may include at least 5 wt % of indigestible oligosaccharides, at least 1 wt % of oligosaccharide consisting of uronic acid remains in terms of dry weight of the composition while total weight of indigestible oligosaccharides is 0.1 - 10 g per portion. Alternatively the composition may content 5-100 mg of nucleotides per 100 g of dry weight of the composition. Alternatively the composition may include 102 - 1013 CFU of bacteria per 1 g of dry weight of the composition.
EFFECT: invention allows to improve intestine maturation, enhance intestinal barrier and so to improve systemic condition of children born by caesarean section as well as promotes prevention and/or treatment of infection and other diseases with children born by caesarean section.
18 cl, 3 tbl, 5 ex
SUBSTANCE: invention relates to compounds of formula in which R1 and R2 independently denote C1-6alkyl; R4 denotes phenyl, substituted with trifluoromethyl if necessary; X denotes hydrogen or methyl; and Y denotes -C(O)R, where R denotes C1-6alkyl; or Y denotes -P(O)(OR5)2, where R5 denotes hydrogen or C1-6alkyl; or pharmaceutically acceptable salts thereof. Said compounds are prodrugs of adenosine A2B receptor. The invention also relates to a pharmaceutical composition which is an adenosine A2B receptor antagonist based on the compound of formula I.
EFFECT: formula I compounds and the pharmaceutical composition can be used in treating different diseases in mammals, such as gastrointestinal disorders, immunological disorders, allergic disorders, neurological disorders, cardiovascular disorders and diseases associated with cell hyperproliferation.
13 cl, 1 tbl, 15 ex
FIELD: medicine, veterinary science.
SUBSTANCE: group of inventions concerns veterinary. A method for improving stool quality in animals consists in regulating the balance of metabolised cations and metabolised anions consumed by an animal in good supply for improving stool quality. A method of changing stool frequency in the animal includes regulating the balance of metabolised cations and metabolised anions consumed by the animal in good supply for changing stool frequency. The composition for changing stool quality and/or frequency in animals contains at least one component chosen from the group including metabolised cations, and at least one component chosen from the group including metabolised anions where the balance of metabolised cations and metabolised anions is regulated by an amount changing stool quality and/or frequency in animals.
EFFECT: group of inventions allows maintaining normal functioning of intestines in animals.
22 cl, 1 tbl, 1 ex
SUBSTANCE: treating moderate house atopic bronchial asthma in the patients with immune deficiency suffering from frequent acute respiratory infections is ensured by administering Grippferon intranasally 5 days a week with a leech therapy accompanied by a subcutaneous allergen-specific immune therapy with causally relevant allergens. The leech therapy is performed by applying one medical leech on the skin in a projection of the thymus twice a day for the period of time with no ARI episodes recorded over the last 3 months. The allergens are administered endolymphatically in the proximal direction from a cuff applied on a forehand, and pressure is maintained at 40 mm Hg for 60 minutes with an underlying basic therapy with the Symbicort preparation.
EFFECT: using the method enables providing the higher clinical effectiveness in anti-recurrent therapy of the frequent ARI episodes in the patients suffering from the moderate form of bronchial asthma, reducing the number and length of the ARI episodes, preserving control over the asthmatic symptoms with reducing a dose and a frequency of the preparations of the bronchial asthma therapy.